Nothing said here yet.
to join the conversation.
| Feld MichaelEVP, Chief Revenue Officer | Sell | 76 | $15.1K | Mon, Oct 26 |
| Feld MichaelEVP, Chief Revenue Officer | Sell | 76 | $14.0K | Mon, Sep 28 |
| Feld MichaelEVP, Chief Revenue Officer | Sell | 165 | $31.1K | Wed, Aug 26 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Thomas H. Kean Jr | Sell | $8.0K | Thu, May 21 | Tue, Jun 2 |
Becton Dickinson (NYSE:BDX) has commercially launched its Liverty TIPS Stent Graft system in the U.S. for portal hypertension treatment.
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Becton, Dickinson and Company will release its fourth-quarter earnings next week, and analysts anticipate a single-digit bottom-line growth.
Becton Dickinson has seen stronger performance in its high growth segments, supported by ongoing product development, clinical trial progress, and a major U.S. manufacturing agreement that was announced before the scheduled fiscal 2026 fourth quarter earnings…
Becton Dickinson has delivered a strong share price run over the past year, which puts fresh focus on whether the current US$200.42 level is grounded in the cash it can generate.
Becton Dickinson (BDX) heads into its fourth quarter fiscal 2026 report with investors focused on recent execution improvements, progress in higher growth businesses, fresh product launches, and a major U.S. manufacturing agreement.
BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.
Investors hold Becton Dickinson (BDX) and Boston Scientific (BSX) for newer products that grow faster than the rest of their sales.
Becton, Dickinson and Company (NYSE:BDX) has steady demand for its medical devices, together with a long history of paying dividends.
Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust.
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease.